hVIVO plc Director's Dealings (7664T)
July 05 2018 - 9:00AM
UK Regulatory
TIDMHVO
RNS Number : 7664T
hVIVO plc
05 July 2018
hVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
London, UK, 5 July 2018: hVIVO plc (AIM: HVO), announces that
application has been made to AIM for the admission of 7,477 new
ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jim Winschel (Non-Executive Director) of new ordinary
shares, under the terms of his letter of appointment as set out in
the Company's announcement of 4 November 2014 which stated that Mr
Ellertson and Mr Winschel had entered into binding commitments to
purchase $20,000 and GBP4,000 of hVIVO plc new ordinary shares
respectively per quarter. Jaime Ellertson waived his Non-Executive
Directors Fee with effect from 1 April 2018 and accordingly at the
same time discontinued his quarterly purchase of shares, which was
40% of his fee.
The New Ordinary Shares represent Mr Winschel's investment for
the quarter ended 30 June 2018. On 5 July 2018, Mr Winschel
invested in an additional 7,477 ordinary shares, at a price of 53.5
pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,223,614 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 11 July 2018. Following
Admission, Mr Winschel will be interested in a total of 73,138
ordinary shares of 5.0p in the Company, representing less than 0.1%
of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
--- -------------------------------------------------------------------------
a) Name Jim Winschel
--- --------------------------- --------------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------------
a) Position/ Non-Executive Director
status
--- --------------------------- --------------------------------------------
b) Initial notification/ Initial Notification
Amendment
--- --------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -------------------------------------------------------------------------
a) Name hVIVO plc
--- --------------------------- --------------------------------------------
b) Legal Entity N/A
Identifier
--- --------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
--- --------------------------- --------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
--- --------------------------- --------------------------------------------
c) Currency GBP
--- --------------------------- --------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) -------------- ---------- -------
Jim Winschel 53.5 7,477
-------------- ---------- -------
--- ---------------------------
e) Aggregated
information
- Aggregated
volume
- Price 7,477
- Aggregated 53.5p
total
GBP4,000.20
--- --------------------------- --------------------------------------------
f) Date of the 5 July 2018
transaction
--- --------------------------- --------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--- --------------------------- --------------------------------------------
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (Director, Investor Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 50 clinical studies,
inoculated over 2500 volunteers and has three first-in-class
therapies currently in development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUGUWAMUPRGWA
(END) Dow Jones Newswires
July 05, 2018 10:00 ET (14:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024